Abstract:Abstract Background Coronavirus disease 2019 (Covid-19) remains a serious health threat worldwide. It is crucial to explore effective treatment measures that reduce mortality. Our aim was to investigate whether low molecular weight heparin (LMWH) can reduce organ injury in patients with Covid-19 pneumonia. Methods A retrospective study was conducted at the Shanghai Public Health Clinical Center. We initiated a LMWH protocol from January 18th 2020. LMWH was injected subcutaneously at 4100U per day until the D-dimer(DD) level returned to normal, or 5-7 days after admission, whichever occurred first. Admitted patients who received LMWH between January 18th and February 17th 2020 were assigned to the LMWH group. Patients admitted between January 18th and February 17th who did not receive LMWH anticoagulant therapy were the control group. All patients in both groups were aged >18 years, were not pregnant, had no tumors and were in accordance with the following inclusion criteria: 1) DD increased on admission; 2) Body mass index(BMI) >30; 3) History of diabetes. The exclusion criteria were: 1) Platelets <30x10 9 /L or fibrinogen <150 mg/dL; 2) Pregnancy and lactation; 3) Presence of blood system diseases; 4) Immunosuppression; 5) Diseases with a potential risk of bleeding; 6) Receiving anticoagulant drugs or antiplatelet drugs during treatment. General clinical information, indicators for renal function, arterial blood gas analyses and blood lactic acid content were recorded in the two groups 0 (Day 0), 3 (Day 3), 7 (Day 7), and 11 (Day 11) and 15 (Day 15) days after admission. Results There were 48 patients in the LMWH group and 74 patients in the control group. General information, including age, gender, co-existing diseases and onset-to-admission time in both groups was similar. Compared to the control group, LMWH treatment improved the estimated glomerular filtration rate (eGFR) reduced the serum creatinine level (Scr), blood urea nitrogen (BUN)，arterial blood carbon dioxide partial pressure (PaCO2) and arterial blood lactic acid content. However, LMWH treatment reduced arterial oxygen partial pressure (PaO2) and arterial oxygen saturation (SaO2). Conclusion LMWH might be beneficial to improve renal function, CO2 discharge and microcirculation during the early phase of Covid-19 patients . Further randomized controlled trials(RCTs) are warranted in order to further investigate this issue. Trial registration ChiCTR, ChiCTR2000034796. Registered 19 July 2020 - Retrospectively registered, http:// www. chictr.org.cn/listbycreater.aspx.

Heparin-azithromycin microparticles show anti-inflammatory effects and inhibit SARS-CoV-2 and bacterial pathogens associated to lung infections

Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and of the storm

Development of a dry powder formulation for pulmonary delivery of azithromycin-loaded nanoparticles

Excipient-Free Inhalable Microparticles of Azithromycin Produced by Electrospray: A Novel Approach to Direct Pulmonary Delivery of Antibiotics

Azithromycin in viral infections

Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease

Low Molecular Weight Heparin Protects Lung, Renal and Microcirculation Function in Patients with Covid-19 Pneumonia

Direct inhibitory effect on viral entry of influenza A and SARS‐CoV‐2 viruses by azithromycin

Nebulized enriched heparin improves respiratory parameters in patients with COVID-19: a phase I/II randomized and triple-blind clinical trial

Promising Antiviral Activity of Agrimonia pilosa Phytochemicals against Severe Acute Respiratory Syndrome Coronavirus 2 Supported with In Vivo Mice Study

Gelatin Stabilizes Nebulized Proteins in Pulmonary Drug Delivery against COVID-19

Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections

Repurposing Astragalus Polysaccharide PG2 for Inhibiting ACE2 and SARS-CoV-2 Spike Syncytial Formation and Anti-Inflammatory Effects

Inhalable Chitosan-Based Hydrogel as a Mucosal Adjuvant for Hydroxychloroquine in the Treatment for SARS-CoV-2 Infection in a Hamster Model

Local Delivery of Azithromycin Nanoformulation Attenuated Acute Lung Injury in Mice

Microenvironment responsive charge-switchable nanoparticles act on biofilm eradication and virulence inhibition for chronic lung infection treatment

Elucidating the Interactions Between Heparin/Heparan Sulfate and SARS-CoV-2-Related Proteins—An Important Strategy for Developing Novel Therapeutics for the COVID-19 Pandemic

Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin

Heparin Mimetics As Potential Intervention for COVID-19 and Their Bio-Manufacturing

ACE2 Receptor‐Targeted Inhaled Nanoemulsions Inhibit SARS‐CoV‐2 and Attenuate Inflammatory Responses